EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

GAD65 Antibody ELISA With Extended Reportable Range: Validation and Guidance for Neurological Practice

Andrew McKeon iD, Dana Olofson, Diana Anissian, Divyanshu Dubey iD, Eoin P Flanagan, Max C Herman, Sarosh R Irani iD, Daniel H Lachance, Maria A Willrich iD, Sean Pittock iD, John R Mills, Anastasia Zekeridou iD

Annals of Clinical and Translational Neurology · 2026-10 · 13 (10) · 2036-2045

DOI: 10.1002/acn3.70378 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 28.03.2026. Verfasst von Andrew McKeon und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Glutamate Decarboxylase, Diabetes Mellitus, Type 1, Autoantibodies, Autoimmune Diseases of the Nervous System. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NIH HHS, National Institute of Neurological Disorders and Stroke.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To (1) validate GAD65‐ELISA detection and quantification for type 1 diabetes mellitus and autoimmune neurological diagnoses, (2) correlate ELISA results (reference range < 5 IU/mL) with established radioimmunoprecipitation assay (RIA; ≤ 0.02 nmol/L), and (3) define ELISA clinical utility and pitfalls.

Methods

Serum performance for diabetes (FDA‐cleared, undiluted) was verified, and neurological laboratory‐developed serum and CSF dilution protocols were validated to extend the reportable range beyond > 250 IU/mL. ELISA and RIA values were correlated, including established neurological RIA cut‐offs (serum ≥ 20 nmol/L; CSF any positive).

Results

ELISA met analytical criteria (precision, accuracy, sensitivity, specificity, reference range) in serum and CSF and was clinically equivalent to RIA for autoimmune diabetes. Neurological ELISA cut‐offs were established at 10,000 IU/mL (serum) and 100 IU/mL (CSF). Precision was better below 10,000 IU/mL (CVs < 20%) than above (CVs 30.8% serum; 26.5% CSF). ELISA–RIA correlation and agreement was stronger below the neurological cut‐off (R 2 = 0.89) than above (R 2 = 0.36). Positive agreement for RIA‐defined neurological disease was 100% in serum and CSF; all serums were > 10,000 IU/mL. Clinical specificity was 97.5% in serum and 100% in CSF, exceeding reported RIA specificity. Screen results > 250 IU/mL spanned a wide range of dilution values; many were below the neurological cut‐off. Most patients with paired serum/CSF positivity showed elevated GAD65 IgG indices.

Interpretation

GAD65 ELISA and RIA have equivalent sensitivity for autoimmune diabetes and neurological testing, with higher specificity for ELISA. A serum cut‐off of 10,000 IU/mL is informative but requires clinical context, and dilution of screen > 250 IU/mL samples is essential for neurological interpretation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glutamate DecarboxylaseDiabetes Mellitus, Type 1AutoantibodiesAutoimmune Diseases of the Nervous SystemHumansEnzyme-Linked Immunosorbent AssayFemaleMaleSensitivity and SpecificityAdultRadioimmunoprecipitation AssayMiddle AgedReference ValuesAdolescent

Stichwörter der Autor:innen

ELISAGAD65ataxiaautoimmunestiff‐person

Substanzen

Glutamate Decarboxylaseglutamate decarboxylase 2Autoantibodies

Autor:innen und Institutionen

  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA.
  • Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.

ORCID-Profile: Andrew McKeon, Divyanshu Dubey, Sarosh R Irani, Maria A Willrich, Sean Pittock, Anastasia Zekeridou

Förderung

  • NINDS NIH HHS
  • NIH HHS
  • National Institute of Neurological Disorders and Stroke
  • National Institutes of Health

Zitieren

APA

McKeon, A., Olofson, D., Anissian, D., Dubey, D., Flanagan, E. P., Herman, M. C., Irani, S. R., Lachance, D. H., Willrich, M. A., Pittock, S., Mills, J. R., & Zekeridou, A. (2026). GAD65 Antibody ELISA With Extended Reportable Range: Validation and Guidance for Neurological Practice. Annals of Clinical and Translational Neurology, 13(10), 2036-2045. https://doi.org/10.1002/acn3.70378

Vancouver

McKeon A, Olofson D, Anissian D, Dubey D, Flanagan EP, Herman MC, et al. GAD65 Antibody ELISA With Extended Reportable Range: Validation and Guidance for Neurological Practice. Annals of Clinical and Translational Neurology. 2026;13(10):2036-2045. doi:10.1002/acn3.70378

BibTeX
@article{McKeon2026,
  author = {McKeon, Andrew and Olofson, Dana and Anissian, Diana and Dubey, Divyanshu and Flanagan, Eoin P and Herman, Max C and Irani, Sarosh R and Lachance, Daniel H and Willrich, Maria A and Pittock, Sean and Mills, John R and Zekeridou, Anastasia},
  title = {GAD65 Antibody ELISA With Extended Reportable Range: Validation and Guidance for Neurological Practice},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2026},
  volume = {13},
  number = {10},
  pages = {2036--2045},
  doi = {10.1002/acn3.70378}
}
Kostenlos starten →